AXGN

In the past six months, Axogen completed the acquisition of BioCircuit Technologies on October 1, 2026, adding NerveTape™ and resulting in a -6.36% stock movement. A $208.7 million public offering of common stock in September 2026 was associated with an -11.47% stock movement. The company reported Q2 2026 financial results on July 29, 2026, showing 23.1% revenue growth and raised full-year guidance, leading to a +0.53% stock movement. A strategic investment in Trace Biosciences in July 2026 to advance Nerve Trace Nerve-Specific Imaging Technology also resulted in a +0.53% stock movement. Q1 2026 financial results reported on April 28, 2026, led to a +6.60% stock movement. Axogen participated in the 24th Annual Morgan Stanley Global Healthcare Conference in September 2026 and the 2026 Bank of America Global Healthcare Conference in April 2026. Additionally, insiders sold $19.9 million worth of shares over the past year with no buying activity, which has been noted as a potential red flag.